| CERTIFICATE MATURITY | 261028 |
| FIXED RATE (STEERING RATE + 10 b.p.) | 1.85 % |
| VOLUME BOUGHT | 25.0 BLN |
| TRADE DAY | 261026 |
| SETTLEMENT DAY | 261027 |
Author: Ravi Shankar
To Nasdaq Copenhagen
26 October 2026
Financial calendar 2027 for the companies of the Nykredit Group
11 February
Publication of Annual Reports 2026 and announcements of Financial Statements of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group
18 March
Annual General Meeting of Totalkredit A/S, Sundkrogsgade 25, DK-2150 Nordhavn.
18 March
Annual General Meeting of Nykredit Bank A/S, Sundkrogsgade 25, DK-2150 Nordhavn.
18 March
Annual General Meeting of Nykredit Realkredit A/S, Sundkrogsgade 25, DK-2150 Nordhavn.
5 May
Publication of Q1 Interim Report 2027 of the Nykredit Realkredit Group.
19 August
Publication of H1 Interim Reports 2027 of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group.
4 November
Publication of Q1-Q3 Interim Report 2027 of the Nykredit Realkredit Group.
Contact
Nykredit Press Relations, tel +45 31 21 06 39
Attachment
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)
1. KEY INFORMATION
| (a) Name of exempt principal trader: | Investec Bank plc |
| (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree |
Pollen Street Group Limited |
| (c) Name of the party to the offer with which exempt principal trader is connected: | Investec is Joint Broker to Pollen Street Group Limited |
| (d) Date dealing undertaken: | 23rd October 2026 |
| (e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A” |
N/A |
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
| Class of relevant security | Purchases/ sales | Total number of securities | Highest price per unit paid/received | Lowest price per unit paid/received |
| Ordinary shares | Purchases | 1,000 | 910 | 908 |
| Ordinary shares | Sales | 2,192 | 929 | 927 |
(b) Cash-settled derivative transactions
| Class of relevant security | Product description e.g. CFD |
Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position |
Number of reference securities | Price per unit |
| N/A | N/A | N/A | N/A | N/A |
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
| Class of relevant security | Product description e.g. call option | Writing, purchasing, selling, varying etc. | Number of securities to which option relates | Exercise price per unit | Type e.g. American, European etc. |
Expiry date | Option money paid/ received per unit |
| N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
(ii) Exercise
| Class of relevant security | Product description e.g. call option |
Exercising/ exercised against | Number of securities | Exercise price per unit |
| N/A | N/A | N/A | N/A | N/A |
(d) Other dealings (including subscribing for new securities)
| Class of relevant security | Nature of dealing e.g. subscription, conversion |
Details | Price per unit (if applicable) |
| N/A | N/A | N/A | N/A |
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
| Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” |
| None |
(b) Agreements, arrangements or understandings relating to options or derivatives
| Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” |
| None |
| Date of disclosure: | 26th October 2026 |
| Contact name: | Priyali Bhattacharjee |
| Telephone number: | +91-9768034903 |
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)
1. KEY INFORMATION
| (a) Name of exempt principal trader: | Investec Bank plc |
| (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree |
Gamma Communications Plc |
| (c) Name of the party to the offer with which exempt principal trader is connected: | Investec is Joint Broker to Gamma Communications Plc |
| (d) Date dealing undertaken: | 23rd October 2026 |
| (e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A” |
N/A |
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
| Class of relevant security | Purchases/ sales | Total number of securities | Highest price per unit paid/received | Lowest price per unit paid/received |
| Ordinary shares | Purchases | 131,730 | 1091.5 | 1091 |
| Ordinary shares | Sales | 111,730 | 1091 | 1091 |
(b) Cash-settled derivative transactions
| Class of relevant security | Product description e.g. CFD |
Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position |
Number of reference securities | Price per unit |
| N/A | N/A | N/A | N/A | N/A |
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
| Class of relevant security | Product description e.g. call option | Writing, purchasing, selling, varying etc. | Number of securities to which option relates | Exercise price per unit | Type e.g. American, European etc. |
Expiry date | Option money paid/ received per unit |
| N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
(ii) Exercise
| Class of relevant security | Product description e.g. call option |
Exercising/ exercised against | Number of securities | Exercise price per unit |
| N/A | N/A | N/A | N/A | N/A |
(d) Other dealings (including subscribing for new securities)
| Class of relevant security | Nature of dealing e.g. subscription, conversion |
Details | Price per unit (if applicable) |
| N/A | N/A | N/A | N/A |
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
| Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” |
| None |
(b) Agreements, arrangements or understandings relating to options or derivatives
| Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” |
| None |
| Date of disclosure: | 26th October 2026 |
| Contact name: | Priyali Bhattacharjee |
| Telephone number: | +91-9768034903 |
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
To Nasdaq Copenhagen
26 October 2026
Financial calendar 2027 for the companies of the Nykredit Group
11 February
Publication of Annual Reports 2026 and announcements of Financial Statements of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group
18 March
Annual General Meeting of Totalkredit A/S, Sundkrogsgade 25, DK-2150 Nordhavn.
18 March
Annual General Meeting of Nykredit Bank A/S, Sundkrogsgade 25, DK-2150 Nordhavn.
18 March
Annual General Meeting of Nykredit Realkredit A/S, Sundkrogsgade 25, DK-2150 Nordhavn.
5 May
Publication of Q1 Interim Report 2027 of the Nykredit Realkredit Group.
19 August
Publication of H1 Interim Reports 2027 of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group.
4 November
Publication of Q1-Q3 Interim Report 2027 of the Nykredit Realkredit Group.
Contact
Nykredit Press Relations, tel +45 31 21 06 39
Attachment
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)
1. KEY INFORMATION
| (a) Name of exempt principal trader: | Investec Bank Plc |
| (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree |
Advanced Medical Solutions Group Plc |
| (c) Name of the party to the offer with which exempt principal trader is connected: | Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc |
| (d) Date dealing undertaken: | 23rd October 2026 |
| (e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A” |
N/A |
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
| Class of relevant security | Purchases/ sales | Total number of securities | Highest price per unit paid/received | Lowest price per unit paid/received |
| Ordinary shares | Purchase | 42,435 | 282.27 | 282.1 |
| Ordinary shares | Sales | 33,690 | 282.5 | 282.25 |
(b) Cash-settled derivative transactions
| Class of relevant security | Product description e.g. CFD |
Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position |
Number of reference securities | Price per unit |
| N/A | N/A | N/A | N/A | N/A |
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
| Class of relevant security | Product description e.g. call option | Writing, purchasing, selling, varying etc. | Number of securities to which option relates | Exercise price per unit | Type e.g. American, European etc. |
Expiry date | Option money paid/ received per unit |
| N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
(ii) Exercise
| Class of relevant security | Product description e.g. call option |
Exercising/ exercised against | Number of securities | Exercise price per unit |
| N/A | N/A | N/A | N/A | N/A |
(d) Other dealings (including subscribing for new securities)
| Class of relevant security | Nature of dealing e.g. subscription, conversion |
Details | Price per unit (if applicable) |
| N/A | N/A | N/A | N/A |
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
| Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” |
| None |
(b) Agreements, arrangements or understandings relating to options or derivatives
| Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” |
| None |
| Date of disclosure: | 26th October 2026 |
| Contact name: | Priyali Bhattacharjee |
| Telephone number: | +91-9768034903 |
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.
To Nasdaq Copenhagen
26 October 2026
Financial calendar 2027 for the companies of the Nykredit Group
11 February
Publication of Annual Reports 2026 and announcements of Financial Statements of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group
18 March
Annual General Meeting of Totalkredit A/S, Sundkrogsgade 25, DK-2150 Nordhavn.
18 March
Annual General Meeting of Nykredit Bank A/S, Sundkrogsgade 25, DK-2150 Nordhavn.
18 March
Annual General Meeting of Nykredit Realkredit A/S, Sundkrogsgade 25, DK-2150 Nordhavn.
5 May
Publication of Q1 Interim Report 2027 of the Nykredit Realkredit Group.
19 August
Publication of H1 Interim Reports 2027 of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group.
4 November
Publication of Q1-Q3 Interim Report 2027 of the Nykredit Realkredit Group.
Contact
Nykredit Press Relations, tel +45 31 21 06 39
Attachment
- Volkswagen Group and NXP Semiconductors, one of the world’s leading automotive semiconductor companies, are expanding their cooperation in automotive semiconductor technology
- NXP has been selected as a strategic technology partner, providing its microcontrollers (MCUs) as a common building block for Group’s future zonal software-defined vehicle architecture
- Common MCU technology reduces complexity and supports scalable deployment across brands and vehicle segments
WOLFSBURG, Germany, Oct. 26, 2026 (GLOBE NEWSWIRE) — Volkswagen Group and NXP Semiconductors today announced ahead of the International Suppliers Fair (IZB) in Wolfsburg that they had agreed on a strategic partnership. NXP’s S32K5 family of microcontrollers (MCUs) is intended to serve as an important building block of Volkswagen Group’s future software-defined vehicle (SDV) architecture, supporting zonal control across all brands and vehicle segments. The first vehicle featuring the new architecture is planned for 2027.
Modern vehicles must support a growing number of digital functions. Managing these functions through separate electronic control units (ECUs) increases complexity in development and parts management and limits scalability. Zonal architecture addresses this challenge by using powerful microcontrollers to consolidate multiple vehicle functions into fewer ECUs.
Next to high-performance processors that provide the central computing power and make complex decisions for AI-enabled functions such as automated driving and advanced infotainment, the S32K5 MCUs serve as the core processors of the vehicle’s zonal controllers. They connect sensors and actuators, collect and process data from specific areas of the vehicle, and manage functions such as lighting, body, comfort, chassis and safety systems. These capabilities provide the foundation for the central computing platform to run AI algorithms and perform advanced functions.
NXP’s S32K5 MCUs enable functions that previously required separate chips and ECUs to be consolidated within zonal controllers, reducing hardware complexity. They are intended to serve as a common building block for the future zonal SDV architecture developed by Rivian and Volkswagen Group Technologies, LLC (RV Tech), the joint venture between Volkswagen Group and Rivian. The architecture is intended to be used across both companies’ vehicles, enabling brand-specific features and experiences.
The partnership is part of Volkswagen Group’s broader semiconductor strategy. Through direct, long-term partnerships with leading semiconductor companies, Volkswagen Group combines its automotive expertise with cutting-edge chip technology to strengthen supply resilience and jointly shape key technologies for future vehicle generations. The approach supports the Group Target Picture 2030 and aims to leverage synergies across brands and regions and harmonize key technologies.
Karsten Schnake, Member of the Extended Executive Committee and Member of the Volkswagen Brand Board of Management responsible for Procurement, said: “Semiconductors are strategic technology for the automotive industry. Over the past years, we have systematically expanded our technology ecosystem and built partnerships with leading companies across the value chain. Our partnership with NXP is another step in this journey, showing how Volkswagen Group is taking a more active role in the semiconductor value chain: defining our technology needs early, leveraging our scale across brands and creating greater long-term planning certainty for both sides.”
Werner Tietz, Member of the Extended Volkswagen Group Executive Committee responsible for Group Research and Development, said: “Our future zonal architecture, developed by RV Tech and supported by strategic technology partners such as NXP, creates a scalable technology foundation for multiple Group brands and vehicle segments. By harmonizing key technologies across the Group, we reduce complexity, leverage scale and accelerate innovation while enabling advanced digital capabilities. This allows us to bring digital innovations to our customers faster and continuously enhance our vehicles throughout their lifecycle.”
Rafael Sotomayor, President and CEO at NXP Semiconductors, said: ”Intelligent, software-defined vehicles must operate safely, securely and reliably. Together with Volkswagen Group and RV Tech, NXP is bringing scalable real-time compute, trusted edge intelligence and continuous software innovation together to create a scalable foundation for the next generation of intelligent vehicles.”
Lars Reger, Executive Vice President and CTO at NXP Semiconductors, said: “Software-defined differentiation is the new auto benchmark, and NXP is excited that the S32K5 family of MCUs has been adopted into RV Tech’s innovative new zonal architecture, one of the most sophisticated approaches to streamlined development and differentiating features in the automotive industry today. As a core processor for the vehicle’s zonal controllers, S32K5 is built for safe real-time compute, fast and secure OTA updates and the consolidation of functions that together create a basis for a flexible, continuously updateable vehicle.”
About NXP Semiconductors
NXP Semiconductors N.V. (NASDAQ: NXPI) is the trusted partner for innovative solutions in the automotive, industrial & IoT, mobile, and communications infrastructure markets. NXP’s “Brighter Together” approach combines leading-edge technology with pioneering people to develop system solutions that make the connected world better, safer, and more secure. The company has operations in more than 30 countries and posted revenue of $12.27 billion in 2025. Find out more at www.nxp.com.
NXP and the NXP logo are trademarks of NXP B.V. All other product or service names are the property of their respective owners. All rights reserved. © 2026 NXP B.V.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8f53a109-f422-4bbf-ac41-155096ef6903
CONTACT: For more information, please contact: Veronika Klofcova Corporate Communications Spokesperson Procurement +420 731 296 057 veronika.klofcova@skoda-auto.cz Jonas Kulawik Corporate Communications Spokesperson Product & Technology, Digitalization +49 (0) 152 2945 2616 jonas.alexander.kulawik@volkswagen.de Americas and Europe Phoebe Francis Tel: +1 737-274-8177 Email: phoebe.francis@nxp.com Asia Pacific Jenny YC Chen Email: jenny.yc.chen@nxp.com
| Company announcement no. 52 2026 | Danske Bank Bernstorffsgade 40 DK-1577 København V Tel. + 45 33 44 00 00 26 October 2026 Page 1 of 2 |
Danske Bank share buy-back programme: transactions in week 43
On 5 February 2026, Danske Bank A/S announced a share buy-back programme for a total of DKK 4.5 billion, with a maximum of 45,000,000 shares, in the period from 9 February 2026 to 29 January 2027, at the latest, as described in company announcement no. 6 2026.
The Programme is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”).
The following transactions were made under the share buy-back programme in week 43:
| Number of shares | VWAP DKK | Gross value DKK | |
| Accumulated, last announcement | 9,913,717 | 342.0146 | 3,390,635,986 |
| 19 October 2026 | 117,511 | 350.3967 | 41,175,467 |
| 20 October 2026 | 178,130 | 348.7178 | 62,117,102 |
| 21 October 2026 | 96,792 | 348.1740 | 33,700,458 |
| 22 October 2026 | 237,390 | 344.2418 | 81,719,561 |
| 23 October 2026 | 257,126 | 339.9015 | 87,397,513 |
| Total accumulated over week 43 | 886,949 | 345.1271 | 306,110,100 |
| Total accumulated during the share buyback programme | 10,800,666 | 342.2702 | 3,696,746,086 |
With the transactions stated above, the total accumulated number of own shares under the share buy-back programme corresponds to 1.324% of Danske Bank A/S’ share capital.
Attached to this corporate announcement, aggregated details on the transactions related to the share repurchase programme are shown by venue.
Danske Bank
Contact: Claus Ingar Jensen, Head of Group Investor Relations, tel. +45 25 42 43 70
| Nasdaq Copenhagen | Number of shares | VWAP DKK | Gross value DKK |
| 19 October 2026 | 73,089 | 350.3899 | 25,609,647 |
| 20 October 2026 | 112,252 | 348.7025 | 39,142,553 |
| 21 October 2026 | 60,313 | 348.1732 | 20,999,370 |
| 22 October 2026 | 148,568 | 344.2467 | 51,144,044 |
| 23 October 2026 | 172,028 | 339.9015 | 58,472,575 |
| Total accumulated over week 43 | 566,250 | 345.0211 | 195,368,190 |
| Total accumulated during the share buyback programme | 6,882,847 | 342.3483 | 2,356,330,912 |
| CBOE Europe | Number of shares | VWAP DKK | Gross value DKK |
| 19 October 2026 | 44,422 | 350.4079 | 15,565,820 |
| 20 October 2026 | 65,878 | 348.7439 | 22,974,551 |
| 21 October 2026 | 36,479 | 348.1753 | 12,701,087 |
| 22 October 2026 | 88,822 | 344.2337 | 30,575,526 |
| 23 October 2026 | 85,098 | 339.9015 | 28,924,938 |
| Total accumulated over week 43 | 320,699 | 345.3142 | 110,741,921 |
| Total accumulated during the share buyback programme | 3,917,819 | 342.1330 | 1,340,415,144 |
Attachment
MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase 3 clinical trial (NCT06018337) met its primary endpoint demonstrating a statistically significant, yet modest improvement in progression-free survival (“PFS”) with trastuzumab pamirtecan (BNT323/DB-1303) compared to investigator’s choice of chemotherapy in chemotherapy-naïve patients with HR+/HER2-low metastatic breast cancer who have progressed on endocrine therapy. At this interim analysis for the secondary endpoint of overall survival (“OS”), data were not mature.
A higher rate of interstitial lung disease (“ILD”) was reported in this trial compared to prior trials with trastuzumab pamirtecan, with most cases being Grade 1 and 2. Severe and fatal events were reported in a small proportion of patients (Grade 3-5). Otherwise, the overall safety profile was consistent with prior clinical trials and no new safety signals were observed.
The available efficacy and safety data, as of this data cut-off date, suggest that the potential benefit to patients would be limited in the context of the HR+/HER2-low metastatic breast cancer treatment landscape. The companies will discuss the data and determine next steps.
BioNTech and DualityBio are developing trastuzumab pamirtecan in three ongoing clinical trials, including two global Phase 3 clinical trials, in HR+/HER2-low metastatic breast cancer (NCT06018337) and in HER2-expressing recurrent endometrial cancer (NCT06340568), as well as in a global Phase 1/2 clinical trial (NCT05150691) in patients with advanced/metastatic solid tumors.
About DYNASTY-Breast02
DYNASTY-Breast02 is a global Phase 3 randomized, multi-center, open-label clinical trial in patients living with HR+/HER2-low metastatic breast cancer whose disease has progressed on at least two lines of prior hormone therapy or within six months of first line hormone therapy plus cyclin-dependent kinase (CDK) 4/6 inhibitor in the metastatic setting. The primary endpoint of the clinical trial is PFS with a key secondary endpoint of OS. In the trial, 541 patients with HER2-low expression (IHC 2+/ISH- and IHC 1+) were randomized 1:1 to receive either trastuzumab pamirtecan or investigator’s choice single-agent chemotherapy (capecitabine, paclitaxel or nab-paclitaxel).
About trastuzumab pamirtecan
Trastuzumab pamirtecan (BNT323/DB-1303) is a third-generation topoisomerase-1 inhibitor-based ADC targeting HER2 being developed by BioNTech and Duality Biologics. Trastuzumab pamirtecan was built from DualityBio’s proprietary Duality Immune Toxin Antibody Conjugates (“DITAC”) platform. HER2 is a surface-expressed protein on solid tumors and has been linked to the aggressive growth and spread of cancer cells.
Trastuzumab pamirtecan is being evaluated in an ongoing Phase 1/2 trial (NCT05150691) in patients with advanced/metastatic solid tumors, in Fern-EC-01, a randomized Phase 3 clinical trial (NCT06340568) evaluating trastuzumab pamirtecan compared with investigator’s choice of single agent chemotherapy in previously treated patients with HER2-expressing advanced recurrent endometrial cancer, and in DYNASTY-Breast02, a randomized Phase 3 clinical trial (NCT06018337) in chemotherapy-naïve patients with HR+/HER2-low metastatic breast cancer who have progressed on endocrine therapy.
About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.
For more information, please visit www.BioNTech.com.
BioNTech Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the collaboration between BioNTech and DualityBio to jointly clinically develop antibody-drug conjugates (ADCs) including trastuzumab pamirtecan (BNT323/DB-1303); the initiation, timing, progress, and results of BioNTech’s research and development programs, including data from the DYNASTY-Breast02 Phase 3 clinical trial (NCT06018337) evaluating trastuzumab pamirtecan in HR+/HER2-low metastatic breast cancer; the expected timing of initiation, enrollment, and completion of trials and related preparatory work and the availability of results; and discussions with regulatory agencies. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.
The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with clinical data, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the impact of tariffs and escalations in trade policy; competition related to BioNTech’s product candidates; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech’s development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market its product candidates, if approved; BioNTech’s ability to manage its development and related expenses; regulatory and political developments in the United States and other countries; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; and other factors not known to BioNTech at this time.
You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended June 30, 2026, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov.These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.
About DualityBio
DualityBio is a clinical-stage innovative biopharmaceutical company dedicated to developing next-generation antibody-drug conjugates (ADCs) for patients with cancer and autoimmune diseases. The Company has successfully built multiple next-generation ADC technology platforms with global intellectual property rights. Grounded in a deep understanding of disease biology, DualityBio has established a robust clinical-stage ADC pipeline and is conducting multiple global, multicenter clinical trials across nearly 20 countries, with over 3,500 patients enrolled to date. Furthermore, DualityBio has entered into several out-licensing collaborations with global pharmaceutical companies and leading innovative biotech firms. Serving as a global engine for ADC innovation, DualityBio continues to develop next-generation novel ADCs, including bispecific ADCs, ADCs with novel payloads, and autoimmune ADCs.
For more information, please visit www.dualitybiologics.com.
CONTACTS
BioNTech
Media Relations
Jasmina Alatovic
Media@biontech.de
Investor Relations
Douglas Maffei, PhD
Investors@biontech.de
DualityBio
Media Relations
PR@dualitybiologics.com
Investor Relations
IR@dualitybiologics.com
